Bio

With 30 years healthcare experience of which 20 years with cellular therapy Troels has a unique background for leading Glycostem through to the approval of one of the first (if not the first) off-the-shelf cellular immunotherapy products. Troels has been part of management teams launching 3 cellular therapies across the world and raising in excess of €160 million. Background as co-founder of a clinical stage cellular therapy and university spin-out company to managing director for public listed companies provides for the broad background needed to understand and react to issues in bringing products to the market. Troels background is commercial, with experience from sales, marketing, business development, investor relations for blue chip healthcare and small biotech start-up companies.